[mamacze]

Thank you all for chiming in on my post and thank you Becky for putting a thumb tack on it.
I too am concerned for patients who have tumor profiling done and can do nothing with the results - ie, when we have no effective treatments for the mutations that are identified.
But (correct me if you think I have been duped, please!!), when I had the profile done;
a gene mutation was identified (PIK3CA G1049S); and the tumor profile report also then identified a promising med that has shown clinical benefit in clinical trial against that particularmutation. (in my case they identified Drugs Associated with Clinical Benefit against this mutation ie, Everolimus or other mTor inhibitors) They also listed relevant available clinical trials with a link on clinical trials.gov. At the moment I am still responding to Herceptin (the tumor they biopsied is what popped up during a Herceptin holiday). But I feel like I have Everolimus in my back pocket as a Plan B when I start to become resistant to Herceptin.
Also,they said this test was covered by my insurance.
My oncologist was intrigued. He said he would get another biopsy done when I do become resistant to Herceptin. I queried the company that did the profiling. They said they only report on mutations that have a corresponding drug associated with clinical benefit; otherwise the test is not helpful to patient or physician.
Do you think I was misled?
I would love to hear your opinions.
Love this Her2 board....
Kim (from CT)